Business
Rallybio Corporation Reports Third Quarter 2021 Financial Results and Recent Business Highlights
-- Initiated FNAIT natural history study to inform frequency of FNAIT risk in broad population and support future potential registration trial -- -- On-track
About this update from Rallybio Corporation
[{"type":"text","content":"\n-- Initiated FNAIT natural history study to inform frequency of FNAIT risk in broad population and support future potential registration trial --\n\n-- On-track to announce in 4Q 2021 additional clinical data from ongoing Phase 1/2 study of RLYB211 for prevention of FNAIT --\n\n-- Executing across preclinical portfolio, with Phase 1 studies for RLYB212 and RLYB116 expected to initiate in 1Q 2022 --\n\n NEW HAVEN, Conn.--(BUSINESS WIRE)--\nRallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare diseases, today reported financial results for the third quarter ended September 30, 2021 and provided an update on recent corporate developments.\n\n“We continue to work with unwavering commitment to deliver transformative impact to people living with severe and rare disorders,” said Martin Mackay, Ph.D., Chief Executive Officer of Rallybio. “In the third quarter, our team focused on execution across our FNAIT franchise and advanced our efforts to better define the patient populations most at risk for disease through the initiation of our natural history study, while continuing to progress RLYB212 toward the clinic for the first quarter of 2022. We plan to report data from our ongoing Phase 1/2 trial of RLYB211 in the fourth quarter, which will provide further insight into the relationship between treatment duration and platelet clearance as well as inform our clinical development strategy for RLYB212. In parallel, we continue to advance efforts across our broader portfolio. We expect to initiate a Phase 1 study of RLYB116, our lead C5 inhibitor, in the first quarter of 2022, and we continue to pursue the best science around the globe to expand our pipeline with new assets and partners.”\n\nRallybio’s current pipeline is focused on addressing diseases in the areas of hematology, immuno-inflammation, maternal fetal health, and metabolic disorders.\n\nRecent 2021 Business Highlights:\n\nIn September 2021, Rallybio initiated a fetal and neonatal alloimmune thrombocytopenia (FNAIT) natural history alloimmunization study. The prospective, non-interventional, multinational study is designed to determine the frequency of women at higher FNAIT risk among expectant mothers of different racial and ethnic c...